メッセージ
折り返しご連絡いたします!
メッセージは20〜3,000文字にする必要があります。
メールを確認してください!
より多くの情報はより良いコミュニケーションを促進します。
正常に送信されました!
折り返しご連絡いたします!
メッセージ
折り返しご連絡いたします!
メッセージは20〜3,000文字にする必要があります。
メールを確認してください!
—— SIMPOR PHARMA
—— Nasir
—— IATEC、アルゼンチン
—— モハメッド Saad
what is the Role of Modular Cleanrooms in the Cell and Gene Therapy Boom?
Enabling Agile, Patient-Centric Manufacturing
CGT products, particularly personalized therapies like autologous CAR-T, demand highly flexible production environments. Modular cleanrooms use prefabricated units that can be quickly assembled, reconfigured, or relocated to match evolving process requirements. This agility allows manufacturers to respond swiftly to clinical trial milestones or commercial demand changes, avoiding the lengthy downtime associated with modifying fixed cleanroom infrastructure. For example, a single modular unit can be repurposed from CAR-T cell processing to viral vector production in weeks, supporting pipeline diversification without costly facility overhauls.
Optimizing Cost and Risk Management
Unlike traditional cleanrooms that require significant upfront capital investment, modular solutions follow a "pay-as-you-grow" model, aligning costs with actual production needs. This is critical for CGT companies, which often manage multiple small-batch therapies with uncertain commercial trajectories. Modular cleanrooms also reduce operational risks through compartmentalized design: each unit operates with independent HVAC and filtration systems, containing cross-contamination risks and allowing isolated maintenance without halting entire production lines. This design lowers compliance validation efforts, as modifications to individual modules do not require re-qualification of the entire facility.

